Sangar V K, Cowan R, Margison G P, Hendry J H, Clarke N W
Cancer Research UK Experimental Radiation Oncology Group, Paterson Institute for Cancer Research, Manchester M20 4BX, UK.
Br J Cancer. 2004 Jan 26;90(2):542-8. doi: 10.1038/sj.bjc.6601538.
The aim of this study was to establish the radiosensitising properties of gemcitabine in a pair of related bladder tumour cell lines with differential radiosensitivity. The radioresistant bladder tumour cell line MGH-U1 and its radiosensitive mutant clone, S40b (both p53 mutant), had SF(2) values (surviving fraction at 2 Gy) of 0.98 and 0.64, respectively (P<0.001). Colony-forming assays showed that at 0.01 microM gemcitabine radiosensitisation occurred only in the S40b cell line (dose-modifying factor (DMF)=1.4). At 0.3 microM (killing 50% of cells), both cell lines were radiosensitised; DMF=2.25 and 1.2 for MGH-U1 and S40b, respectively. These data suggest that gemcitabine is an effective radiosensitiser in bladder cancer cell lines, with greater sensitisation in the radioresistant parental line-a feature that should be useful in a clinical setting.
本研究的目的是在一对具有不同放射敏感性的相关膀胱肿瘤细胞系中确定吉西他滨的放射增敏特性。放射抗性膀胱肿瘤细胞系MGH-U1及其放射敏感突变克隆S40b（两者均为p53突变体）的SF(2)值（2 Gy时的存活分数）分别为0.98和0.64（P<0.001）。集落形成试验表明，在0.01 microM吉西他滨浓度下，仅S40b细胞系出现放射增敏作用（剂量修正因子(DMF)=1.4）。在0.3 microM（杀死50%的细胞）时，两个细胞系均出现放射增敏；MGH-U1和S40b的DMF分别为2.25和1.2。这些数据表明，吉西他滨在膀胱癌细胞系中是一种有效的放射增敏剂，在放射抗性亲代细胞系中具有更强的增敏作用——这一特性在临床环境中应具有实用性。
